Cefdinir Inhibitor CAS No. 91832-40-5

Cat. No.	Name	Size	Price	Add Cart
KI0651	Cefdinir	100 mg	$154

Chemical Characteristic

Product Name	Cefdinir
Synonyms	Omnicef, FK482
CAS No.	91832-40-5
Molecular Weight	395.41
Formula	C₁₄H₁₃N₅O₅S₂
Chemical Name	(6R,?7R)?-7-?[[(2Z)?-?2-?(2-?amino-?4-?thiazolyl)?-?2-?(hydroxyimino)?acetyl]?amino]?-?3-?ethenyl-?8-?oxo-5-?thia-?1-?azabicyclo[4.2.0]?oct-?2-?ene-?2-?carboxylic acid
Smiles	[C@@H]12SCC(=C(N1C(=O)[C@@H]2NC(=O)/C(=N/O)/c1nc(sc1)N)C(=O)O)C=C
Chemical Structure

Biological activities

Cefdinir is a third generation cephalosporin antibiotic. Cefdinir is very active against the Enterobacteriaceae with a MIC50 value of ??0.03-8 µg/mL. In contrast to cefixime, cefdinir inhibits Staphylococcus aureus with a MIC90 value of 1 µg/mL. Cefdinir also inhibits Pneumococci, beta-hemolytic streptococci, Haemophilus influenzae, Moraxella catarrhalis, and pathogenic Neisseria spp. With MIC90 values ranging from 0.12 to 0.5 µg/mL.^[1] In another in vitro study, the MIC90 values of cefdinir for Staphylococcus aureus (30 strains), Staphylococcus epidermidis (24 strains), and Staphylococcus hominis(10 strains) are 0.25, 0.06, and 0.125 mg/L, respectively. The MIC90 values of cefdinir for Staphylococcus xylosus(15 strains), Staphylococcus capitis (11 strains), and Staphylococcus saprophyticus (10 strains) are 0.5, 0.5, and 4 mg/L, respectively.^[2] In studies using β-lactamase-nonproducing (βLAC^-) and -producing (βLAC⁺) Staphylococcus aureus strains, the PD50s of cefdinir are 11 and 2.3 for preventing subcutaneous abscess and 2.7 and 2.3 mg/kg for preventing lethal systemic infection, respectively. In studies using βLAC^-??and βLAC⁺??Haemophilus influenzae, the PD50s of cefdinir are 5.8 and 3.1 mg/kg for preventing lethal systemic infection.^[3]

References

[1] Briggs BM, et al. In vitro activity evaluations of cefdinir (FK482, CI-983, and PD134393). A novel orally administered cephalosporin. Diagn Microbiol Infect Dis. 1991, 14(5): 425-434. [2] Marchese A, et al. Antistaphylococcal activity of cefdinir, a new oral third-generation cephalosporin, alone and in combination with other antibiotics, at supra- and sub-MIC levels. J Antimicrob Chemother. 1995, 35(1): 53-66. [3] Cohen MA, et al. In vivo therapeutic efficacy of cefdinir (FK482), a new oral cephalosporin, against Staphylococcus aureus and Haemophilus influenzae in mouse infection models. Diagn Microbiol Infect Dis. 1994, 18(1): 41-47.

Please click here to fill online order form, and we will make sure to supply you product with detail information. This process usually takes between 24 to 48 hours, depending on products stock avaliability. All inquires and subsequent projects are handled in the strictest confidence and will be backed by a confidentiality agreement if required.

KareBay^TM provides scientists and clinicians with a wide range of biotechnological products and science lab supplies for chemical research and analyzing life processes. KareBay's extensive capabilities include commercializing reagents and kits, manufacturing biotech products and providing contract research services to organizations worldwide. Our many global labs, offices, and business partners enable KareBay to extend its products and services to its customer base around the world.

Our products are used for research, laboratory and further evaluation purposes. They are not for human use.

About

KareBay^TM Biochem
Sitemap
Blog

Custom Services

Organic Synthesis
Peptide Synthesis
Antibody Production
Protein Expression
Bioconjugation Service
Immunoassry Service
Molecular Biology Services
Oligonucleotides Synthesis
RNA Synthesis Service
cGMP Peptide Synthesis Services
cGMP Organic Synthesis Services

Biochemical Products

Small Molecule Inhibitors
Bioactive Compounds
Primary Antibodies
Peptides
Amino Acids
Reagents
Fluorescent dyes
Intermediates
PCR

KareBay^TM Biochem, Inc.
11 Deer Park Drive, Suite 102A
Monmouth Junction, NJ 08852

Telephone

: 732-823-1545

Fax

: 732-823-1349

product@karebaybio.com
service@karebaybio.com
support@karebaybio.com